https://www.ascopost.com/videos/2022-asco-gastrointestinal-cancers-symposium/yu-sunakawa-on-gastric-cancer-predicting-treatment-related-toxicities-with-biomarkers/
https://ascopost.com/videos/2022-asco-gastrointestinal-cancers-symposium/yu-sunakawa-on-gastric-cancer-predicting-treatment-related-toxicities-with-biomarkers/
https://www.ascopost.com/videos/2022-asco-gastrointestinal-cancers-symposium/kohei-shitara-on-gastric-and-esophageal-cancers-long-term-follow-up-on-nivolumab-plus-chemotherapy/
https://ascopost.com/videos/2022-asco-gastrointestinal-cancers-symposium/kohei-shitara-on-gastric-and-esophageal-cancers-long-term-follow-up-on-nivolumab-plus-chemotherapy/
https://www.ascopost.com/news/january-2022/addition-of-nivolumab-to-oxaliplatin-based-chemotherapy-for-her2-negative-unresectable-advanced-or-recurrent-gastric-or-gastroesophageal-junction-cancer/
https://ascopost.com/news/january-2022/addition-of-nivolumab-to-oxaliplatin-based-chemotherapy-for-her2-negative-unresectable-advanced-or-recurrent-gastric-or-gastroesophageal-junction-cancer/
https://www.ascopost.com/news/january-2022/first-line-nivolumabcabozantinib-vs-sunitinib-for-advanced-renal-cell-carcinoma-patient-reported-outcomes/
https://ascopost.com/news/january-2022/first-line-nivolumabcabozantinib-vs-sunitinib-for-advanced-renal-cell-carcinoma-patient-reported-outcomes/
https://www.ascopost.com/podcasts/relatlimab-plus-nivolumab-improves-pfs-in-patients-with-previously-untreated-metastatic-or-unresectable-melanoma/
https://ascopost.com/podcasts/relatlimab-plus-nivolumab-improves-pfs-in-patients-with-previously-untreated-metastatic-or-unresectable-melanoma/
https://www.ascopost.com/news/january-2022/effect-of-recent-prior-radiotherapy-on-adverse-events-in-patients-receiving-immune-checkpoint-inhibitors/
https://ascopost.com/news/january-2022/effect-of-recent-prior-radiotherapy-on-adverse-events-in-patients-receiving-immune-checkpoint-inhibitors/
https://www.ascopost.com/news/january-2022/addition-of-anti-lag-3-antibody-relatlimab-to-nivolumab-in-previously-untreated-patients-with-advanced-melanoma/
https://ascopost.com/news/january-2022/addition-of-anti-lag-3-antibody-relatlimab-to-nivolumab-in-previously-untreated-patients-with-advanced-melanoma/
https://www.ascopost.com/news/january-2022/interim-radiographic-assessment-for-adaptive-dosing-of-combination-immunotherapy-in-advanced-melanoma/
https://ascopost.com/news/january-2022/interim-radiographic-assessment-for-adaptive-dosing-of-combination-immunotherapy-in-advanced-melanoma/
https://www.ascopost.com/news/january-2022/association-of-hla-a03-with-outcomes-of-immune-checkpoint-inhibition-for-advanced-cancers/
https://ascopost.com/news/january-2022/association-of-hla-a03-with-outcomes-of-immune-checkpoint-inhibition-for-advanced-cancers/
https://www.ascopost.com/issues/december-25-2021/epov-ian-chau/
https://ascopost.com/issues/december-25-2021/epov-ian-chau/
https://www.ascopost.com/issues/december-25-2021/2021-fda-approvals-of-drugs-for-cancer-treatment/
https://ascopost.com/issues/december-25-2021/2021-fda-approvals-of-drugs-for-cancer-treatment/
https://www.ascopost.com/news/december-2021/first-line-nivolumab-vs-sorafenib-in-advanced-hepatocellular-carcinoma-effect-on-overall-survival/
https://ascopost.com/news/december-2021/first-line-nivolumab-vs-sorafenib-in-advanced-hepatocellular-carcinoma-effect-on-overall-survival/
https://www.ascopost.com/news/december-2021/study-suggests-lack-of-benefit-with-the-addition-of-immune-checkpoint-inhibition-to-chemotherapy-in-low-pd-l1-expressing-gastric-or-esophageal-adenocarcinomas/
https://ascopost.com/news/december-2021/study-suggests-lack-of-benefit-with-the-addition-of-immune-checkpoint-inhibition-to-chemotherapy-in-low-pd-l1-expressing-gastric-or-esophageal-adenocarcinomas/
https://www.ascopost.com/news/december-2021/immune-checkpoint-inhibitor-treatment-in-patients-aged-65-and-older-with-advanced-melanoma-association-between-sex-and-survival/
https://ascopost.com/news/december-2021/immune-checkpoint-inhibitor-treatment-in-patients-aged-65-and-older-with-advanced-melanoma-association-between-sex-and-survival/
https://www.ascopost.com/news/december-2021/long-term-outcomes-from-checkmate-067-nivolumabipilimumab-nivolumab-or-ipilimumab-in-advanced-melanoma/
https://ascopost.com/news/december-2021/long-term-outcomes-from-checkmate-067-nivolumabipilimumab-nivolumab-or-ipilimumab-in-advanced-melanoma/
https://www.ascopost.com/issues/december-10-2021/radiation-therapy-for-hpv-related-oropharyngeal-squamous-cell-carcinoma-prospects-and-controversies/
https://ascopost.com/issues/december-10-2021/radiation-therapy-for-hpv-related-oropharyngeal-squamous-cell-carcinoma-prospects-and-controversies/
https://www.ascopost.com/issues/december-10-2021/epov-nabil-f-saba/
https://ascopost.com/issues/december-10-2021/epov-nabil-f-saba/
https://www.ascopost.com/issues/december-10-2021/optimizing-the-use-of-checkpoint-inhibitors-in-recurrent-or-metastatic-head-and-neck-cancer/
https://ascopost.com/issues/december-10-2021/optimizing-the-use-of-checkpoint-inhibitors-in-recurrent-or-metastatic-head-and-neck-cancer/
https://www.ascopost.com/issues/december-10-2021/applying-research-data-to-clinical-practice-in-managing-head-and-neck-cancer/
https://ascopost.com/issues/december-10-2021/applying-research-data-to-clinical-practice-in-managing-head-and-neck-cancer/
https://www.ascopost.com/issues/december-25-2021/sotigalimab-plus-nivolumab-in-anti-pd-1pd-l1-refractory-melanoma/
https://ascopost.com/issues/december-25-2021/sotigalimab-plus-nivolumab-in-anti-pd-1pd-l1-refractory-melanoma/
https://www.ascopost.com/news/december-2021/epov-keith-flaherty/
https://ascopost.com/news/december-2021/epov-keith-flaherty/
https://www.ascopost.com/issues/december-10-2021/dreamseq-trial-in-advanced-melanoma-with-braf-mutations-start-with-immunotherapy/
https://ascopost.com/issues/december-10-2021/dreamseq-trial-in-advanced-melanoma-with-braf-mutations-start-with-immunotherapy/
https://www.ascopost.com/news/december-2021/immunomodulatory-effects-of-neoadjuvant-nivolumab-chemotherapy-in-nsclc/
https://ascopost.com/news/december-2021/immunomodulatory-effects-of-neoadjuvant-nivolumab-chemotherapy-in-nsclc/
https://www.ascopost.com/videos/sitc-2021/stephanie-schmidt-on-nsclc-the-immunomodulatory-impact-of-neoadjuvant-chemotherapy-and-immune-based-treatments/
https://ascopost.com/videos/sitc-2021/stephanie-schmidt-on-nsclc-the-immunomodulatory-impact-of-neoadjuvant-chemotherapy-and-immune-based-treatments/
https://www.ascopost.com/issues/december-25-2021/impact-of-time-of-day-of-immune-checkpoint-inhibitor-infusion-on-overall-survival-in-patients-with-metastatic-melanoma/
https://ascopost.com/issues/december-25-2021/impact-of-time-of-day-of-immune-checkpoint-inhibitor-infusion-on-overall-survival-in-patients-with-metastatic-melanoma/
https://www.ascopost.com/issues/november-25-2021/adjuvant-immunotherapy-the-next-chapter-in-advancements-in-renal-cell-carcinoma/
https://ascopost.com/issues/november-25-2021/adjuvant-immunotherapy-the-next-chapter-in-advancements-in-renal-cell-carcinoma/
https://www.ascopost.com/issues/november-25-2021/epov-pilar-garrido/
https://ascopost.com/issues/november-25-2021/epov-pilar-garrido/
https://www.ascopost.com/issues/november-25-2021/checkmate-743-supports-survival-benefit-of-nivolumab-plus-ipilimumab-in-malignant-pleural-mesothelioma/
https://ascopost.com/issues/november-25-2021/checkmate-743-supports-survival-benefit-of-nivolumab-plus-ipilimumab-in-malignant-pleural-mesothelioma/
https://www.ascopost.com/issues/november-25-2021/durable-responses-in-metastatic-nsclc-are-we-getting-closer-to-a-cure/
https://ascopost.com/issues/november-25-2021/durable-responses-in-metastatic-nsclc-are-we-getting-closer-to-a-cure/
https://www.ascopost.com/news/november-2021/immunotherapy-followed-by-targeted-therapy-yields-greater-overall-survival-in-patients-with-braf-v600-mutated-advanced-melanoma/
https://ascopost.com/news/november-2021/immunotherapy-followed-by-targeted-therapy-yields-greater-overall-survival-in-patients-with-braf-v600-mutated-advanced-melanoma/
https://www.ascopost.com/news/november-2021/long-term-outcomes-with-nivolumab-plus-ipilimumab-in-active-melanoma-brain-metastases/
https://ascopost.com/news/november-2021/long-term-outcomes-with-nivolumab-plus-ipilimumab-in-active-melanoma-brain-metastases/
https://www.ascopost.com/news/november-2021/checkmate-214-longer-treatment-free-survival-with-immunotherapy-vs-targeted-therapy-in-patients-with-advanced-renal-cell-carcinoma/
https://ascopost.com/news/november-2021/checkmate-214-longer-treatment-free-survival-with-immunotherapy-vs-targeted-therapy-in-patients-with-advanced-renal-cell-carcinoma/
https://www.ascopost.com/issues/november-10-2021/showcasing-50-years-of-advances-in-cancer-research-and-treatment/
https://ascopost.com/issues/november-10-2021/showcasing-50-years-of-advances-in-cancer-research-and-treatment/
https://www.ascopost.com/news/october-2021/nivolumab-for-relapsed-malignant-mesothelioma-improvements-in-progression-free-and-overall-survival/
https://ascopost.com/news/october-2021/nivolumab-for-relapsed-malignant-mesothelioma-improvements-in-progression-free-and-overall-survival/
https://www.ascopost.com/issues/october-25-2021/epov-bruna-pellini/
https://ascopost.com/issues/october-25-2021/epov-bruna-pellini/
https://www.ascopost.com/issues/october-25-2021/pretreatment-levels-of-circulating-tumor-dna-may-predict-long-term-survival-in-nsclc/
https://ascopost.com/issues/october-25-2021/pretreatment-levels-of-circulating-tumor-dna-may-predict-long-term-survival-in-nsclc/
https://www.ascopost.com/issues/october-25-2021/epov-florian-lordick/
https://ascopost.com/issues/october-25-2021/epov-florian-lordick/
https://www.ascopost.com/issues/october-25-2021/checkmate-649-long-term-data-support-nivolumab-plus-chemotherapy-but-not-nivolumab-plus-ipilimumab-in-gastric-cancer/
https://ascopost.com/issues/october-25-2021/checkmate-649-long-term-data-support-nivolumab-plus-chemotherapy-but-not-nivolumab-plus-ipilimumab-in-gastric-cancer/
https://www.ascopost.com/issues/november-10-2021/epov-omid-hamid/
https://ascopost.com/issues/november-10-2021/epov-omid-hamid/
https://www.ascopost.com/issues/november-10-2021/secombit-trial-evaluates-optimal-treatment-sequencing-in-braf-mutated-melanoma/
https://ascopost.com/issues/november-10-2021/secombit-trial-evaluates-optimal-treatment-sequencing-in-braf-mutated-melanoma/
https://www.ascopost.com/news/october-2021/two-studies-examine-the-efficacy-of-immunotherapy-for-leptomeningeal-carcinomatosis/
https://ascopost.com/news/october-2021/two-studies-examine-the-efficacy-of-immunotherapy-for-leptomeningeal-carcinomatosis/
https://www.ascopost.com/news/october-2021/nivolumablow-dose-ipilimumab-produces-responses-in-patients-with-msi-hdmmr-metastatic-colorectal-cancer/
https://ascopost.com/news/october-2021/nivolumablow-dose-ipilimumab-produces-responses-in-patients-with-msi-hdmmr-metastatic-colorectal-cancer/
https://www.ascopost.com/videos/esmo-congress-2021/filippo-pietrantonio-and-federica-morano-on-colorectal-cancer-and-the-maya-trial-strategy-temozolomide-ipilimumab-and-nivolumab/
https://ascopost.com/videos/esmo-congress-2021/filippo-pietrantonio-and-federica-morano-on-colorectal-cancer-and-the-maya-trial-strategy-temozolomide-ipilimumab-and-nivolumab/
https://www.ascopost.com/news/october-2021/fda-perspective-on-drug-dosing-in-oncology-from-more-is-better-to-less-can-be-more/
https://ascopost.com/news/october-2021/fda-perspective-on-drug-dosing-in-oncology-from-more-is-better-to-less-can-be-more/
https://www.ascopost.com/news/october-2021/aacr-cancer-progress-report-2021-showcases-50-years-of-advances-in-cancer-research-and-treatment/
https://ascopost.com/news/october-2021/aacr-cancer-progress-report-2021-showcases-50-years-of-advances-in-cancer-research-and-treatment/
https://www.ascopost.com/issues/october-10-2021/neoadjuvant-atezolizumab-under-study-in-mesothelioma/
https://ascopost.com/issues/october-10-2021/neoadjuvant-atezolizumab-under-study-in-mesothelioma/
https://www.ascopost.com/news/october-2021/fda-pipeline-recent-reviews-designations-applications-and-authorizations-in-the-oncology-space/
https://ascopost.com/news/october-2021/fda-pipeline-recent-reviews-designations-applications-and-authorizations-in-the-oncology-space/
https://www.ascopost.com/news/october-2021/axicabtagene-ciloleucel-for-adult-patients-with-primary-mediastinal-b-cell-lymphoma-real-world-outcomes/
https://ascopost.com/news/october-2021/axicabtagene-ciloleucel-for-adult-patients-with-primary-mediastinal-b-cell-lymphoma-real-world-outcomes/
https://www.ascopost.com/issues/september-25-2021/nivolumab-for-adjuvant-treatment-of-urothelial-carcinoma/
https://ascopost.com/issues/september-25-2021/nivolumab-for-adjuvant-treatment-of-urothelial-carcinoma/
https://www.ascopost.com/issues/september-25-2021/guideline-rapid-update-provides-new-direction-on-the-care-of-patients-with-residual-disease-in-locally-advanced-esophageal-cancer/
https://ascopost.com/issues/september-25-2021/guideline-rapid-update-provides-new-direction-on-the-care-of-patients-with-residual-disease-in-locally-advanced-esophageal-cancer/